Compare CNK & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNK | TMDX |
|---|---|---|
| Founded | 1984 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.8B |
| IPO Year | 2007 | 2019 |
| Metric | CNK | TMDX |
|---|---|---|
| Price | $29.23 | $100.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | $33.70 | ★ $148.22 |
| AVG Volume (30 Days) | ★ 1.9M | 763.2K |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.22% | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | 1.04 | ★ 4.87 |
| Revenue | ★ $3,115,000,000.00 | $605,494,000.00 |
| Revenue This Year | $11.01 | $24.25 |
| Revenue Next Year | $3.70 | $18.75 |
| P/E Ratio | $28.28 | ★ $22.26 |
| Revenue Growth | 2.15 | ★ 37.13 |
| 52 Week Low | $21.60 | $88.51 |
| 52 Week High | $34.01 | $156.00 |
| Indicator | CNK | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 53.14 | 37.47 |
| Support Level | $27.24 | $97.66 |
| Resistance Level | $30.94 | $120.60 |
| Average True Range (ATR) | 0.92 | 5.39 |
| MACD | -0.22 | -0.00 |
| Stochastic Oscillator | 38.97 | 1.91 |
Cinemark Holdings Inc is a geographically diverse operator in the motion picture exhibition industry in the United States. The company generates revenue from filmed entertainment box office receipts and concession sales, with additional revenue from screen advertising, screen rentals, and other revenue streams, such as transactional fees, vendor marketing promotions, studio trailer placements, meeting rentals, and electronic video games located in some of the theatres. Cinemark manages its business under two reportable segments: U.S. markets and international markets. The majority of its revenue is generated from the U.S. markets segment.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.